Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines regulation

Pharmacists should continue to follow Lyrica guidance, says PSNC

Pharmacists should continue to follow NHS England guidance and refer generic prescriptions for pregabalin back to the prescriber if they know it has been written for the treatment of neuropathic pain, says PSNC. In the image, Pfizer logo

Source: pio3 / Shutterstock.com

Pfizer intends to appeal the High Court ruling on Lyrica’s second medical use patent

Pharmacists should continue to follow NHS England guidance and refer generic prescriptions for pregabalin back to the prescriber if they know it has been written for the treatment of neuropathic pain, according to the Pharmaceutical Services Negotiating Committee (PSNC).

The advice from the national negotiators comes 12 days after Pfizer lost its High Court action to protect the second medical use patent of Lyrica, its branded version of pregabalin.

“The judgment, which may be subject to appeal, has not affected the situation for pharmacists and GPs – NHS England requires pharmacists to refer generic prescriptions back to the prescriber, if they are aware it is for neuropathic pain, and it requires prescribers to prescribe the brand for neuropathic pain,” the PSNC said on its website on 22 September 2015. “Pharmacists can dispense prescriptions written for pregabalin, unless they have reason to believe that the prescription is for the treatment of neuropathic pain.”

The PSNC says it will continue to push the Department of Health and NHS England for “clear and unequivocal guidance” as and when the Lyrica situation changes.

The latest advice from the PSNC appears to contradict the statement it made immediately after the High Court decision. It said then that pharmacists could “freely dispense generic pregabalin where the prescription is written generically”.

Pfizer has already announced that it plans to appeal against the High Court ruling.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069414

Readers' comments (1)

  • Will someone somewhere make their mind up on this and soon!!!

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Pharmacists should continue to follow NHS England guidance and refer generic prescriptions for pregabalin back to the prescriber if they know it has been written for the treatment of neuropathic pain, says PSNC. In the image, Pfizer logo

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.